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Abstract: Vigabatrin, the first therapeutic agent to be approved by the Food and Drug Admin-
istration for the treatment of infantile spasms, as well as for adjunctive use in the treatment of 
refractory complex partial epilepsy, represents an important advance for patients with difficult-
to-manage epilepsy. This review summarizes the complex history, chemistry, and pharmacology, 
as well as the clinical data leading to the approval of vigabatrin for infantile spasms in the US. 
The long path to its approval reflects the visual system and white matter toxicity concerns with 
this agent. This review provides a brief description of these concerns, and the regulatory safety 
monitoring and mitigation systems that have been put in place to enhance benefit over risk.
Keywords: vigabatrin, infantile spasms, monotherapy
Introduction
Vigabatrin, an irreversible inhibitor of gamma aminobutyric acid (GABA) transaminase 
(GABA-T) was specifically designed to be a suicide substrate for this enzyme and 
thereby augment tissue GABA concentrations for the treatment of epilepsy. It was first 
licensed as an antiepileptic agent in the UK and the Republic of Ireland in 1989. By the 
late 1990s, it had been accepted into mainstream clinical practice in the care of adult 
and pediatric patients in over 40 countries.1 In the US, vigabatrin has experienced a 
stuttering regulatory course. In 1998, the Food and Drug Administration (FDA) notified 
the manufacturer, Hoechst Marion Roussel, that vigabatrin was “not approvable” based 
on the data submitted up until that time, in the light of the then emerging concerns about 
vigabatrin. These concerns included reports of severe, persistent visual field defects 
noted in association with the use of vigabatrin.2,3 Interestingly, the development of 
vigabatrin in the US had been delayed for several years due to earlier concerns about 
white matter toxicity (intramyelinic edema) encountered in experimental animals,4 
then resumed when such toxicity could not be demonstrated in humans.1 After years 
of having being shelved and after renewed efforts by a different company (Ovation 
Pharmaceuticals, now Lundbeck), vigabatrin received FDA approval in 2009 for the 
treatment of infantile spasms, as well as for refractory complex partial seizures.
The indication for infantile spasms can be considered quite remarkable because 
vigabatrin is the first FDA-approved treatment for this very difficult to treat disorder. 
Adrenocorticotropic hormone (ACTH), the legacy treatment for infantile spasms, has 
never been formally approved for that use in the US and is now entering regulatory 
hearings at the US FDA. As described here, infantile spasms represents a rare and 
distinctive disorder of multiple etiologies and presents many challenges to the conduct 
of an adequately powered controlled study.
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Infantile spasms represent a devastating childhood 
epileptic syndrome, and has been described as one of the 
“catastrophic epilepsies of infancy”.5 What makes infantile 
spasms such a form of devastating epilepsy is the combination 
of extremely difficult to control seizures and its associa-
tion with mental retardation. The seizures involve violent 
flexion or extension spasms that occur in clusters. This 
clinical presentation, accompanied by a distinctive high-
voltage chaotic electroencephalogram (EEG) pattern called 
hypsarrhythmia and developmental delay, is called West 
syndrome. Hypsarrhythmia is the characteristic interictal 
EEG pattern, consisting of a triad of features, including 
high amplitude and disorganized or “chaotic” background 
and multifocal independent spike discharges. Infantile 
spasms has an incidence of 0.25–0.42 per 1000 live births 
and a prevalence of 0.14–0.52 per 1000 children. Infantile 
spasms are slightly more common in males.6 This syndrome 
represents the response of the brain to a severe insult dur-
ing a specific developmental window, and can result from 
hypoxic-ischemic encephalopathy, infections, focal cortical 
dysplasia, intraventricular hemorrhage, tuberous sclerosis, 
Down syndrome, trauma, Aicardi syndrome, neonatal hypo-
glycemia, Ohtahara syndrome, and pyridoxine deficiency. 
When a specific etiology is not apparent, the syndrome is 
classified as cryptogenic. Advances in genetic testing have 
shown that mutations within the aristaless-related homeobox 
gene on chromosome Xp22.13 is associated with an X-linked 
infantile spasms syndrome.7 The cyclin-dependent kinase-
like or serine-threonine kinase 9 gene located on the Xp22.3 
chromosome is also a cause of X-linked infantile spasms. 
Mutations in the lissencephaly-1 and the doublecortin genes 
are related to classical lissencephaly, double cortex syndrome, 
and infantile spasms.8
Epileptic spasms have a variety of clinical and electro-
graphic forms. The typical clinical spasms is a flexor spasms 
that is a rapid flexion of the neck, trunk, and extremities 
lasting less than two seconds, which is frequently followed 
by a sustained tonic phase for up to 10 seconds.9 On occa-
sions, spasms can be extensor, with a rapid extension of the 
neck and arching of the back, or a mixture of both flexion 
and extension postures. The intensity of spasms can vary, 
even within a cluster, from brief eye rolling or subtle head 
nodding to a violent shock-like event. On occasion, children 
will become upset or cry in between spasms. Spasms typi-
cally occur in clusters, most commonly when waking from 
sleep. Electrographically, there are a variety of EEG patterns 
which can accompany the spasms, but the most common is a 
generalized medium to high amplitude slow wave, followed 
by an electrodecrement and attenuation.6 Children with 
symptomatic infantile spasms can have focal findings both 
clinically and electrographically.
Historically, the first-line treatment of infantile spasms 
has been ACTH. The availability of vigabatrin in much of 
Europe, and the finding that it was often efficacious in the 
treatment of infantile spasms, resulted in its adoption as the 
preferred agent, because of its relative ease of use. In Europe 
and many other countries, vigabatrin is considered the initial 
drug of choice. The European expert opinion statement from 
2007 recommended vigabatrin as the treatment of choice 
for patients with tuberous sclerosis and other symptomatic 
etiologies.10 In the US, where vigabatrin was not FDA-
approved until very recently, ACTH has been considered 
the initial drug of choice, even though it awaits regulatory 
approval at this time.
Many additional agents and treatments have been tried 
as second and third options, including valproic acid, pyri-
doxine, zonisamide, topiramate, levetiracetam, intravenous 
immunoglobulin, and the ketogenic diet, each with a hand-
ful of uncontrolled open-label studies or retrospective case 
series. Resective surgery for some symptomatic cases (in 
particular focal cortical dysplasia) has been successful.
In 2004 the “Practice Parameter: Medical Treatment of 
Infantile Spasms” was released by the American Academy 
of Neurology and the Child Neurology Society. Their con-
clusions on vigabatrin included “1. Vigabatrin is possibly 
effective for the short-term treatment of infantile spasms 
(level C, class III and IV evidence), 2. Vigabatrin is also pos-
sibly effective for the short-term treatment of infantile spasms 
in the majority of children with tuberous sclerosis (level C, 
class III and IV evidence), and 3. Serious concerns about 
retinal toxicity in adults suggest that serial ophthalmologic 
screening is required in patients on vigabatrin. However, 
data are insufficient to make recommendations regarding 
the frequency or type of screening that would be of value 
in reducing the prevalence of this complication in children 
(level U, class IV studies)”.11
Vigabatrin was finally approved by the FDA on August 
21, 2009 with indications for refractory complex partial 
seizures in adults and infantile spasms in children aged one 
month to two years. All health care providers using vigaba-
trin will need to enroll in the SHARE (Support, Help and 
Resources for Epilepsy) program and complete the Risk 
Evaluation and Mitigation Strategy (REMS) course. This 
was specifically designed to reduce the risk of vision loss, 
and includes baseline and regular vision monitoring, frequent 
assessments of effectiveness, and education. It is suggested to 
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discontinue the medication if patients fail to show substantial 
improvement in seizures within three months. Vigabatrin is 
now the only medication in the US with an FDA approval 
for infantile spasms.12
Pharmacology
The chemical structure of vigabatrin is 4-amino-6-hexenoic 
acid (γ-vinyl GABA). It was designed specifically to achieve 
irreversible inhibition of GABA-T,13 which is present in 
neurons and glia and causes oxidative deamination of GABA 
to succinic semialdehyde.
Unlike several other inhibitors of GABA-T which also 
display some activity against the enzyme responsible for 
the synthesis of GABA (glutamic acid decarboxylase) 
vigabatrin is selective in its antagonism of GABA degra-
dation.14 The structures of GABA and vigabatrin are shown 
in Figure 1. The obvious structural similarity is responsible 
for the ability of vigabatrin to interact with GABA-T. The 
presence of the vinyl moiety in the structure of vigabatrin 
renders it a mechanism-based suicide substrate which is 
covalently (and irreversibly) bound to the enzyme. Only 
new enzyme synthesis can restore GABA-T activity. Thus, 
even a single dose produces a lasting, dose-dependent 
inhibition of brain GABA-T in experimental animals, and 
elevated GABA levels are seen for at least 24 hours.13 
After a dose of 1500 mg/kg of vigabatrin in mice, GABA 
levels increased to a maximum of 650% of control in four 
hours,15 Levels of the excitatory amino acids, glutamate and 
aspartate, reached a nadir of approximately 80% of control 
values in about the same duration. Noninvasive measure-
ment of brain GABA levels in humans by the application 
of 1H magnetic resonance spectroscopy has permitted the 
demonstration of 2.5- to 3-fold elevations in GABA levels 
in the brains of epileptic patients treated with standard 
doses of vigabatrin.16,17
Our present understanding of GABA receptor activation 
is based on its action at postsynaptic GABA(A) receptors 
(GABAAR), which have a specific subunit composition, and 
differently assembled extrasynaptic receptors. GABAAR 
exhibit low affinity for GABA (and thus require the high 
levels of GABA reached by synaptic release) and rapid 
inactivation (such that the receptor is ready for a new signal 
again). They also possess a γ-subunit that is required for 
allosteric interaction by benzodiazepines. The inhibition 
mediated by presynaptic release of GABA has been called 
phasic inhibition. The extrasynaptic receptors, on the other 
hand, have a stoichiometry that substitutes a α4 subunit (for 
the α1 or α2 in the synaptic receptors mediating phasic inhi-
bition); these receptors are highly sensitive to low ambient 
GABA concentrations and the inhibition produced is last-
ing, and is called tonic inhibition. They lack a γ-subunit that 
confers benzodiazepine sensitivity to the synaptic receptors, 
and are assembled instead with a δ-subunit. Neurosteroids, 
related to progesterone and pregnenolone derivatives,  activate 
extrasynaptic GABA receptors mediating tonic inhibition. 
This is also the postulated mechanism for ganaxalone, a 
synthetic neurosteroid that has shown some activity against 
infantile spasms.18
The action of vigabatrin likely augments both phasic and 
tonic inhibition by enhancing GABA concentration in differ-
ent pools. Benzodiazepines like nitrazepam have been used to 
treat infantile spasms in the past. In a randomized multicenter 
study, nitrazepam was found to be comparable with ACTH 
in efficacy and better in tolerability.19 The impact on tonic 
inhibition can be viewed as having some similarity to one 
of the potential actions of ACTH, which can stimulate the 
adrenal formation of deoxycorticosterone and its tetrahydro 
metabolite, which is a strong agonist at extrasynaptic recep-
tors. This potential convergence in the mechanistic basis of 
seemingly unrelated compounds used to treat infantile spasms 
is illustrated in Figure 2.
In the developing brain, there may also be an impor-
tant effect of ambient GABA on presynaptic GABAAR to 
increase the strength of GABAergic synaptic transmission. 
GABA γ-Vinyl GABA (Vigabatrin, VGB)
COOH COOH
NH2 NH2
Figure 1 Structures of GABA and VGB.
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Low concentrations of GABA or zolpidem, an agonist at 
the benzodiazepine binding site, increased the frequency 
of miniature GABAergic synaptic currents,20 representing 
a positive feedback loop. This effect was seen only in rat 
pups up to postnatal day 14, and has been demonstrated in 
the cerebellum. The presence of these presynaptic GABAAR 
was confirmed by immunocytochemistry.20 The role of such 
receptors as targets for modifying spasms remains to be 
confirmed.
Efficacy of vigabatrin  
in infantile spasms
The efficacy and safety of vigabatrin for use in infants has 
been evaluated in numerous studies (see Table 1). Many of 
the studies were retrospective reviews or add-on combination 
trials. However, some were open-label monotherapy trials 
or randomized comparative trials versus hydrocortisone 
and ACTH. We describe selected studies that contributed 
significantly to the development of vigabatrin for infantile 
spasms.
An early large European retrospective analysis involving 
250 infants evaluated vigabatrin as initial therapy for infantile 
spasms.21 Of the initial 250 enrolled, 192 were determined to 
have classic spasms, based on semiology, age of onset, and 
EEG criteria. Hypsarrhythmia (typical or atypical) had been 
documented in 75% of the patients. The mean dose of vigaba-
trin used was 105 mg/kg. The efficacy in this survey is among 
the highest reported. Cessation of spasms occurred in 69% of 
patients with cryptogenic spasms and 60% of patients with 
symptomatic spasms, excluding tuberous sclerosis. Among 
the responders, 82% registered their response within one week 
after initiation of treatment. A dramatic response rate of 96% 
was achieved in treating infantile spasms attributed to tuber-
ous sclerosis. This report, like many others, found a low rate 
of adverse effects (14%), mainly somnolence. Importantly, 
only two of the original 250 patients discontinued therapy 
because of adverse effects. Resolution of hypsarrhythmia 
was not specifically reported in this report.
Appleton et al22 reported on a randomized, placebo-
controlled, blinded study of treatment of infantile spasms 
using vigabatrin employing a distinctive design. In their 
study (n = 40, all meeting EEG criteria), the randomized, 
placebo-controlled phase was held for five days, after which 
all patients were eligible to have vigabatrin on an open-label 
basis. The average percent reduction in spasms in the 
vigabatrin-treated group was 78% compared with 26% in the 
ACTH
Deoxycorticosterone
(DOC)
Tetrahydro-DOC
(THDOC)
VGB
Increased ambient GABA
Neurosteroids
ganaxalone
GABA
α1βxγ2
α2βxγ2
α4/6βxδ
Figure 2 Schematic demonstrating a common target of action shared by many forms of therapy. Treatment with adrenocorticotropic hormone stimulates the adrenal 
production of tetrahydrodeoxycorticosterone which can activate extrasynaptic gamma aminobutyric acid receptors which mediate tonic inhibition. Increased ambient gamma 
aminobutyric acid produced by vigabatrin treatment may have a similar effect, as also the treatment with ganaxalone a neurosteroid investigational drug. The α4βxδ subunit 
containing extrasynaptic receptors are readily activated by modest levels of ambient gamma aminobutyric acid to produce a “lasting” current to sustain tonic activation. 
Adapted with permission from Auvin S, Sankar R. Antiinflammatory treatments for seizure syndromes and epilepsy. In: Rho JM, Sankar R, Stafstrom CE, editors. Epilepsy: 
Mechanisms, Models, and Translational Perspectives. New York, NY: CRC Press/Taylor and Francis; 2010.
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placebo-treated group (P = 0.020). This study did not enroll 
any patients with tuberous sclerosis, a subset whose spasms 
have emerged to be uniquely responsive to treatment with 
vigabatrin. At the end of the 24-week trial period, 15 of the 
original 40 patients were spasm-free on monotherapy with 
vigabatrin, while four more were seizure-free on vigabatrin in 
combination with other medications. Separation between two 
groups was not significant because both groups had been on 
vigabatrin except for the first five days of the 24-week period. 
The study did establish that initial therapy of vigabatrin was 
effective, safe, and well tolerated.
The first prospective, randomized, open-label trial com-
paring vigabatrin and ACTH as first-line monotherapy for 
infantile spasms was published in 1997.23 In a crossover study, 
42 patients with untreated infantile spasms were randomized 
to vigabatrin 100–150 mg/kg/day or depot ACTH at 10 IU/day. 
Patients who did not respond to initial therapy by three weeks 
were crossed over to the other treatment arm. After the first 
stage of treatment, 48% of those treated with vigabatrin and 
74% treated with ACTH became seizure-free (P = 0.12). Dur-
ing the second stage, 92% of patients who failed vigabatrin 
became seizure-free on ACTH, and 40% of patients who 
failed ACTH became seizure-free on vigabatrin (P = 0.052). 
Overall, 46% treated with vigabatrin and 81% treated with 
ACTH became seizure-free (P = 0.007). More patients in the 
ACTH-treated group showed normalization of the EEG, and 
improvements in EEG occurred earlier. Side effects (som-
nolence, hypotonia, irritability) were more prevalent with 
ACTH (37%) while the 13% adverse event rate for vigabatrin 
was similar to that reported by Aicardi et al.21 This study also 
confirmed that all but one of 11 responders to vigabatrin did 
so within eight days of therapy, and 100 mg/kg/day seemed 
the optimal dose. Furthermore, this study demonstrated that 
vigabatrin was more effective as initial therapy in children 
with brain malformations or tuberous sclerosis, while ACTH 
was superior in children who developed infantile spasms after 
hypoxic-ischemic insults. It is important to note that the dose 
of ACTH used in this study is substantially less than what has 
emerged as the standard in the US (150 IU/m2/day).
Important clinical trial data for the FDA’s deliberations 
on the approval of vigabatrin come from the multicenter, 
randomized, single-masked (as to dose) study by Elterman 
et al.24,25 Initial results were published in 2001 in peer-
reviewed form24 and the results including a larger popula-
tion were presented in abstract form at the 2005 meeting 
of the American Epilepsy Society.25 This multicenter, ran-
domized, single-blinded study evaluated 220 subjects who 
had not been treated with ACTH, prednisone, or valproic 
acid. They were randomized into two groups, ie, low-dose 
(18–36 mg/kg/day) or high-dose (100–148 mg/kg/day). 
A strict definition of treatment response was used (ie, within 
the first 14 days of therapy, free of spasms for at least seven 
consecutive days, and absence of spasms or hypsarrhythmia 
on an eight-hour EEG).
Those who did not respond to the low-dose treatment in 
14 days entered an open-label phase during which the dose of 
vigabatrin could be freely titrated according to response and/or 
tolerability. Only 18% were considered treatment responders 
by the strict definition, but 26% were considered responders if 
the 14-day window was extended. Eighty-eight percent of the 
responders remained spasms-free during the entire study. The 
response rate of the high-dose group (26%) was significantly 
higher than that of the low-dose group (11%). In addition, 
in concordance with other studies, patients with tuberous 
sclerosis (58%) had higher response rates than symptomatic 
(20%) or cryptogenic (37%) patients.
In a separate abstract at the same meeting, the same 
group26 reported their safety data for vigabatrin. Overall, 
vigabatrin was well tolerated, with only 5.4% of patients 
having adverse effects classified as related to vigabatrin that 
caused a discontinuation of the drug. Only 2.9% of serious 
adverse effects noted were classified as vigabatrin-related. 
There are important differences in this study, which con-
firmed the safety recorded by earlier studies, but achieved a 
lower rate of efficacy. The inclusion criteria permitted patients 
up to 24 months of age, and duration of spasms for up to three 
months, which most likely contributed to the observed lower 
rate of response. Further, those who responded beyond the 
first two weeks are not counted in the comparison between 
groups. Thus, the response rate of 58% among patients with 
tuberous sclerosis and infantile spasms compares quite well 
with the initial observations of Chiron et al27 who studied 
patients during the first year of life and reported an 86% 
response rate for infants with tuberous sclerosis.
The United Kingdom Infantile Spasms Study com-
pared the effect of vigabatrin with that of hormone therapy 
(prednisolone or tetracosactide depot) on developmental 
and epilepsy outcomes when the children were evaluated 
at 12–14 months of age.28 Absence of spasms was similar 
in the final clinical assessment, ie, hormone 41/55 (75%) 
versus vigabatrin 39/51 (76%), as were the developmental 
outcomes determined by the Vineland Adaptive Behav-
ior Scale (VABS). The VABS scores were hormone 78⋅6 
(SD 16⋅8) versus vigabatrin 77⋅5 (SD 12⋅7). Among patients 
considered to be cryptogenic, hormone therapy resulted in a 
higher developmental outcome (hormone 88.2 [17.3] versus 
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78.9 [14.3]). This study excluded children with a diagnosis 
of, or at high risk of, tuberous sclerosis, and thus eliminated 
that group that is considered to represent the strongest ben-
eficiaries of receiving therapy with vigabatrin.
Role of vigabatrin in treatment  
of tuberous sclerosis-associated  
infantile spasms
Chiron et al reported on a prospective trial comparing vigaba-
trin with hydrocortisone as initial treatment for infantile 
spasms attributable to tuberous sclerosis. This randomized, 
crossover study utilized vigabatrin at 150 mg/kg/day or hydro-
cortisone 15 mg/kg/day as initial treatment. Nonresponders 
were crossed over at the end of one month of treatment. All 
the patients who were first treated with vigabatrin (11/11) 
were spasms-free compared with 5/11 hydrocortisone infants 
(P , 0.01). All the nonresponders to hydrocortisone became 
spasms-free after being crossed over to vigabatrin. Mean 
time to disappearance of infantile spasms was 3.5 days on 
vigabatrin versus 13 days on hydrocortisone (P , 0.01). 
This study was responsible for establishing the special place 
of vigabatrin in the treatment of infantile spasms in patients 
with tuberous sclerosis. It is worth pointing out that such a 
high response rate is seldom seen in even so-called benign 
epileptic syndromes of childhood.
Vigabatrin is considered safe and effective. Retinal toxic-
ity and white matter changes on magnetic resonance imaging 
(MRI) are the effects that merit separate discussion. How-
ever, the common side effects encountered commonly in the 
various studies include drowsiness/somnolence, nystagmus, 
hyperexcitability/hyperkinesia, insomnia, fever, memory 
impairment, depression, and confusion. Less frequently 
encountered are axial hypertonia, hypotonia, agitation/ 
irritability, asthenia, laryngitis, myoclonus, diarrhea, weight 
gain, and vomiting. Rare cases of psychotic reactions, mild 
anemia, and decreased liver function tests (aspartate amin-
otransferase and alanine aminotransferase) have also been 
reported. Overall, in comparison with many other antiepi-
leptic drugs, vigabatrin is well tolerated.1,21,22,29
Retinal toxicity
One of the most discussed and concerning adverse effects 
of therapy with vigabatrin is retinal toxicity leading to 
visual field constriction. Reports of visual field deficits have 
appeared in the literature since 1997.30 In various studies, this 
effect has been documented in up to 40% of treated patients. 
In addition to visual field loss, abnormal funduscopic 
examination, including “pale disc”, mild optic nerve pallor, 
retinal artery narrowing, and problems with visual acuity, 
color discrimination, and contrast sensitivity have been 
reported. Electroretinography (ERG) shows bilateral retinal 
dysfunction with preferential cone system dysfunction. The 
exact pathology is still unclear, but may be two-fold. First, 
the increase of GABA in the retina is likely to have a role.3 
Second, there may be a relationship between retinal damage, 
vigabatrin, and exposure to light. In the rat retina, administra-
tion of vigabatrin produced a decrease in GABA-T activity 
to undetectable levels and a five-fold increase in GABA.31,32 
In a study of chronic vigabatrin exposure in rats, vigabatrin 
for 45 days produced a decrease in visual tests, including 
photopic ERG, flicker response, and oscillatory potentials.33 
The authors described disorganization of the outer retina, as 
well as damage to the inner and outer cone segments, most 
prominent in the central areas with a decrease in numbers 
in up to 20% of photoreceptors. The toxicity of vigabatrin to 
retinal cells is likely affected by development. In the rabbit 
retina, the fraction of amacrine cells capable of taking up and 
accumulating vigabatrin was very small at postnatal day 1 and 
increased to near-adult levels by 10 days postnatum.34
It is still not entirely clear if the toxicity is related to the 
cumulative dose or if retinal involvement improves after dis-
continuation of the drug.35 There is a positive trend in one ret-
rospective review of higher doses and longer treatment periods 
correlating with visual field constriction, abnormal ERG, and 
abnormal visual-evoked potentials (VEPs),36 although these 
findings have not been consistent. Somewhat encouragingly 
for short-term treatment of infantile spasms with vigabatrin, 
a study of children observed that the most severe damage was 
not observed in the youngest patient.37 More recently, a Finnish 
study of 16 children with a history of treatment of infantile 
spasms with vigabatrin tested the subjects with kinetic perim-
etry between six and 12 years and encountered only mild visual 
field loss in one patient and normal fields in 15.38 Neverthe-
less, careful monitoring for discernible signs of retinal injury 
should be stressed, and has resulted in the Risk Evaluation and 
Mitigation Strategy (REMS) described below.
As part of REMS, vision testing is required at baseline, 
at least every three months during therapy, and at least once 
within three to six months after discontinuation. While ERG 
and VEPs are recommended, these studies are often difficult 
to accomplish, given the age of the patient population with 
infantile spasms (http://www.lundbeckshare.com/pg510_info_ 
physicians.aspx).12 Thus, periodic ophthalmologic examina-
tions (at initiation of therapy, and subsequently, every three 
months while on treatment, and three to six months after 
discontinuation of therapy), while mandated, may or may 
Neuropsychiatric Disease and Treatment 2010:6submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
738
Lerner et al
not include ERG and VEP testing. It is also suggested that, 
because of the risk of permanent vision loss, vigabatrin should 
be withdrawn from a pediatric patient treated for infantile 
spasms (one month to two years of age) who fails to show 
substantial clinical benefit within 2–4 weeks of treatment 
initiation, or sooner if treatment failure becomes obvious. A 
recommended screening algorithm based on evidence-based 
review of visual function testing in patients treated with 
vigabatrin has been published recently.39 Evaluation that 
includes perimetry is suggested only for children over the 
age of nine years.
A critical role for the amino acid taurine in mediating 
vigabatrin-associated retinal ganglion cell toxicity has been 
demonstrated in rats and mice.40,41 Animals treated with 
vigabatrin had 67% lower levels of taurine than controls. The 
hypothesis that the addition of taurine-rich foods or direct 
supplements may prevent or slow down the development of 
the retinal cell lesions has been proposed by the authors. In 
addition, this study demonstrated that limiting light exposure 
might minimize cellular injury. However, excessive limiting 
of visual stimuli in very young patients may impact adversely 
on neural plasticity leading to ocular cortical organization 
and contribute to risk for amblyopia.
White matter changes
The observation of intramyelinic edema and vacuolation of 
myelin of the brain in rats has been alluded to.4 During the 
period following the initial observation, human studies in adults 
using MRI and VEPs reassured investigators that these findings 
in animals may have very limited significance for humans.
Transient MRI abnormalities unrelated to underlying 
cause have been seen in children and adults treated with 
vigabatrin. Areas of abnormality included the basal ganglia, 
thalamus, anterior commissure, corpus callosum, and brain-
stem.42 Wheless et al43 reviewed 332 MRIs from 205 infants 
with infantile spasms and rereviewed MRIs from 668 chil-
dren and adults with complex partial seizures. Abnormali-
ties were defined as any hyperintensity on T2-weighted or 
fluid-attenuated inversion-recovery sequences that were 
diffusion restriction negative and not explained by specific 
pathology. Infants treated with vigabatrin were statistically 
more likely to have MRI abnormalities than those not treated 
with vigabatrin. Resolution of the MRI changes was seen 
in 66% of these patients. Another series involving infants 
(22 subjects, 34 MRIs) confirmed transient white matter 
signal changes.44 An example of such lesions from one of 
our patients is shown in Figure 3. It should be noted that the 
Figure 3 A1 and A2) show axial T2 weighted images of a normal baby aged five months. B1 and B2) show a five-month-old patient who had received vigabatrin for eight 
weeks. The magnetic resonance image was obtained due to abnormal eye movement. Magnetic resonance imaging shows high T2 weighted intensity in the thalamus and 
globus pallidus (arrow in B1) and tegmental portion of the pons (arrow in B2). Vigabatrin was discontinued. C1 and C2) Follow-up magnetic resonance imaging of the same 
patient three months later shows normal signal in the thalamus and pontine tegmentum.
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REMS program does not address monitoring for white matter 
lesions by MRI for infants treated with vigabatrin.
Conclusion
Vigabatrin, the only presently approved therapy for infantile 
spasms in the US, has shown efficacy and tolerability, as well 
as relative safety (especially compared with the available 
options, including nontreatment),45 representing a meaningful 
advance in the treatment of this catastrophic childhood epi-
leptic encephalopathy. Availability of vigabatrin for infantile 
spasms is especially meaningful to those patients in whom 
it is a manifestation of tuberous sclerosis. Guidelines have 
been developed to monitor for visual system toxicity, and 
typical use will be limited to a few months, enhancing the 
benefit to risk ratio.
Disclosure
Dr Sankar is a member of the speakers’ bureau of Lundbeck 
Inc., the supplier of the Sabril brand of vigabatrin in the 
US. He also serves on the speakers’ bureau of Glaxo-Smith-
Kline and UCB Pharma at present and is an advisor to 
Glaxo-Smith-Kline and NeuroTherapeutics Pharma.
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